Premenstrual Dysphoric Disorder (PMDD): A Clinical Guide

Premenstrual Dysphoric Disorder (PMDD): A Clinical Guide

Author: Min Geraets | BNatMed | Naturopath & Medical Herbalist

For many people, the menstrual cycle occurs quietly in the background, predictable, rhythmic and uneventful.  For others, there is a distinct shift each month.  A window of time where emotional resilience narrows, reactivity increases and their internal world feels markedly different.

With Premenstrual Dysphoric Disorder (PMDD), this shift is not subtle.  It is profound, cyclical and often destabilising until help is sought.

Clients may describe a sense of ‘losing themselves’ in their luteal phase, only to return to baseline days later with the onset of menstruation.  Relationships strain, cognition becomes foggy and mood darkens.  Then, just as abruptly, clarity returns.  This cyclical pattern is one of the most clinically significant diagnostic clues, yet it is frequently overlooked.

Beyond PMS: A neuroendocrine sensitivity disorder

PMDD is a severe, cyclical disorder of mood and behaviour, that arises in the luteal phase of the menstrual cycle and quickly resolves with the onset of menstruation.  It has been historically conceptualised as an extreme variant of premenstrual syndrome (PMS).  Contemporary research, however, has reframed PMDD as a disorder of central nervous system sensitivity to normal ovarian hormone fluctuations, rather than a condition driven by absolute hormone excess or deficiency.1

This distinction is not merely semantic; it fundamentally alters the clinical approach. Individuals with PMDD typically exhibit normal circulating levels of oestradiol and progesterone, yet demonstrate marked emotional, cognitive, and somatic symptoms in response to cyclical hormonal changes.  As such, PMDD is best understood as a neuroendocrine sensitivity disorder, situated at the intersection of reproductive endocrinology, neurobiology, stress physiology and psychosocial context.1

Epidemiological data suggest that approximately 3-8% of menstruating individuals meet strict diagnostic criteria for PMDD, while a larger proportion experience subthreshold symptoms that nonetheless result in meaningful impairment.  The condition is associated with:

  • Significant reductions in quality of life
  • Increased occupational and relational impairment
  • Elevated risk of suicidal ideation and behaviour.1

Despite this, PMDD remains under-recognised in both conventional and complementary care settings.1

Diagnostic framework and clinical presentation

PMDD is defined by the DSM-5 as requiring at least five symptoms in the final week before menses, improving within a few days of onset, and minimal or absent post-menses.  Primary symptoms include:

  • Markedly depressed mood, feelings of hopelessness or self-deprecating thoughts 
  • Marked anxiety, tension or feelings of being on 'edge'
  • Marked affective lability 
  • Persistent and marked irritability or anger or increased interpersonal conflicts.2

Additional symptoms may include:

  • Decreased interest in usual activities (work, school, friends, hobbies)
  • Subjective sense of difficulty concentrating 
  • Fatigue or low energy
  • Marked change in appetite, overeating or specific food cravings
  • Hypersomnia or insomnia 
  • A subjective sense of being overwhelmed or out of control 
  • Physical symptoms (breast tenderness or swelling, bloating, weight gain, headaches, or joint or muscle pain).2

A key clinical point is cyclicity.  Symptoms must be prospectively charted across at least two cycles to confirm diagnosis, helping differentiate PMDD from underlying mood disorders with premenstrual exacerbation.2

As PMDD cannot be diagnosed by a blood test, tools such as the Daily Record of Severity of Problems (DRSP) can assist in establishing temporal patterns and confirming cyclicity.  Clinically, this process also provides valuable insight into individual symptom expression and potential triggers, forming the basis for personalised treatment. 

Pathophysiology: Integrating emerging mechanisms

Neurosteroid sensitivity and GABA dysregulation 

Emerging evidence strongly implicates altered sensitivity to neuroactive steroids, particularly allopregnanolone, a neuroactive metabolite of progesterone.

Allopregnanolone modulates GABA-A receptors, typically exerting calming, anxiolytic effects.  In PMDD, however:

  • GABA-A receptor response appears altered or paradoxical to normal luteal phase increases in progesterone and its metabolites
  • Instead of calming, allopregnanolone may induce anxiety, irritability, or dysphoria.2

This helps explain why:

  • Ovarian hormone levels are often normal in PMDD
  • Ovulation suppression can relieve symptoms
  • SSRIs demonstrate unusually rapid efficacy in PMDD.2

From a naturopathic perspective, this reframes progesterone not as inherently deficient or excessive, but as a neuromodulatory trigger in a sensitised system.  Clinically, interventions that support neurotransmitter balance and nervous system stability may be beneficial, rather than solely focusing on hormonal modulation.

HPA axis dysregulation and stress reactivity 

Research has highlighted dysregulation of the HPA axis in PMDD, linking stress physiology to symptom severity.2  

Key features include:

  • Altered cortisol patterns 
  • Heightened stress sensitivity 
  • Interaction with inflammatory pathways.

The luteal phase may represent a period of reduced stress tolerance, where the threshold for overwhelm is significantly lowered.  This creates a layered vulnerability:

  • Hormonal fluctuation alters neurosteroid signalling
  • Stress response systems are less adaptive 
  • Cognitive control is reduced 
  • Emotional regulation becomes more effortful.1

In this context, relatively minor stressors can feel disproportionally intense.  This aligns with clinical observations: stress often exacerbates PMDD severity, and clients frequently report worsening symptoms during periods of increased demand, disrupted sleep or emotional or physical strain.

Serotonergic interactions 

Serotonin plays a central role in mood regulation and has been implicated in PMDD.  Fluctuations in oestrogen and progesterone influence serotonergic activity at multiple levels, including synthesis, receptor expression and reuptake.  Oestrogen generally enhances serotonergic tone, while progesterone metabolites may exert more complex modulatory effects.3

In PMDD, there is evidence of altered serotonin transporter function and receptor sensitivity, contributing to mood instability during the luteal phase.  The rapid therapeutic response to SSRIs in PMDD, further supports a unique interaction between serotonergic systems and reproductive hormones.2

Clinically, this reinforces the relevance of nutritional co-factors involved in serotonin synthesis, including tryptophan and vitamin B6.

Neuroinflammation and immune activation 

A developing area of interest is the role of neuroinflammation in PMDD.  While not yet fully defined, there is growing interest in how immune signalling interacts with mood regulation.  Pro-inflammatory cytokines have been shown to affect neurotransmitter pathways, influencing mood and behaviour.  Potential mechanisms include:

  • Cytokine-induced alterations in neurotransmitter metabolism 
  • Activation of the kynurenine pathway
  • Effects of neuroplasticity and mood regulation.4

Clinically, this raises important questions:

  • Are there drivers of inflammation present (dietary, gut-related, environmental)?
  • Does the client experience other inflammatory conditions?
  • Is there a cyclical pattern to inflammatory symptoms?

While not all PMDD presentations will have a strong inflammatory component, for some clients this may represent a key piece of the puzzle, thus anti-inflammatory strategies may support symptom reduction in a subset of clients.

Trauma, interoception and neural processing 

One of the more nuanced aspects of PMDD lies in how the brain interprets internal physiological changes.

Trauma, whether early life or later, can:

  • Dysregulate limbic system function
  • Heighten interoceptive awareness (the perception and interpretation of internal bodily signals)
  • Amplify emotional responses to physiological changes.1

In PMDD, these interoceptive disturbances interact with cyclical hormonal fluctuations, amplifying distress during the luteal phase as ordinary body sensations are experienced as more intense or life threatening.1

Altered neural processing, particularly in circuits integrating emotional and sensory information, links trauma and interoception bidirectionally, with impaired bodily awareness exacerbating emotional dysregulation and vice versa.1

Clinical assessment: A naturopathic framework 

A comprehensive assessment should include:

1. Symptom tracking

  • Daily symptom tracking (DRSP tool)
  • Identification of luteal phase onset and symptom timing.

2. Mental health screening

  • Depression and anxiety scales
  • Suicide risk assessment (must be approached with appropriate referral pathways).

3. Differential diagnosis

  • Laboratory evaluation should be included to rule out thyroid disease, iron deficiency, vitamin D insufficiency and other metabolic contributors that can produce similar symptoms to PMDD.

4. Nutritional status

  • Blood glucose regulation
  • Micronutrient insufficiency (vitamin D, magnesium, iron, B6).

5. Stress and lifestyle factors

  • Sleep quality
  • Alcohol intake
  • Occupational, relational and relationship stress
  • Exercise habits.

6. Trauma and psychosocial history

  • Gentle, client-led exploration
  • Early life stress
  • Current relational dynamics
  • Referral where appropriate.

Therapeutic approaches

1. Dietary strategies

  • Anti-inflammatory foods (Fatty fish, extra virgin olive oil, berries, green leafy vegetables, garlic, turmeric): Help to reduce underlying inflammatory activity and oxidative imbalance, which are linked to mood changes, pain and behavioural symptoms.  Anti-inflammatory nutrients (including antioxidants and polyphenols) can lower pro-inflammatory cytokines and improve the body’s stress and immune responses, which may otherwise worsen symptoms during the luteal phase.  Research suggests these compounds can reduce premenstrual symptom severity, likely by supporting neurotransmitter function, reducing inflammation and promoting overall brain health.5
  • Stabilise blood glucose (protein-rich meals, reduced refined sugars): During the luteal phase, blood sugar instability may exacerbate irritability, fatigue, cravings and mood swings.6 Ensuring regular, balanced meals with protein, fibre, complex carbohydrates and healthy fats can provide sustained energetic, metabolic and neurochemical activity throughout the day.7

2. Nutritional supplementation

  • Magnesium (200-400 mg/day): May support mood regulation and reduce irritability, anxiety, nervous tension and fluid retention.8  Magnesium glycinate is highly bioavailable and beneficial for neuromuscular relaxation, while magnesium citrate has comparable bioavailability and is best suited to support bowel motility.
  • Calcium (1000-1200 mg/day): Low serum levels have been observed in individuals with PMS.  Calcium supplementation has been associated with a reduction in premenstrual complaints (particularly fluid retention and pain) during the luteal phase.8,9  Calcium and magnesium share similar gastric absorption pathways and can inhibit the uptake of the other when taken in high doses.  It is, therefore, best to dose these two minerals at least two hours apart.
  • Vitamin D (1000-4000 IU/day): Vitamin D plays a key role in calcium metabolism and antioxidant activity, and deficiency has been linked to PMS.  A 2019 randomised clinical trial in vitamin D–deficient students with PMS found that supplementation significantly reduced inflammatory markers (IL-10 and IL-12), increased total antioxidant capacity (TAC), and improved overall PMS symptom scores.10
  • Vitamin B6 (30-50 mg/day): Functions to regulate the production of GABA and serotonin, supports the maintenance of intracellular magnesium levels, and assists in relieving fluid retention and low mood associated with PMS.8,11
  • Omega-3 fatty acids (EPA/DHA, 1-2 g/day): Their anti-inflammatory, neuroprotective and anti-depressant properties can be particularly beneficial for stabilising mood in PMDD.  Omega-3's, particularly EPA, has been shown to improve depressive symptoms in individuals with elevated inflammatory markers (CRP, IL-6 and TNF-α).12  Omega 3 supplementation may be especially helpful for clients with PMDD who present with a pronounced inflammatory profile.

3. Herbal medicine 

Evidence for herbal interventions in PMDD specifically is limited but extrapolated from PMS research and mechanistic plausibility.

  • Ashwagandha (Withania somnifera) may help support the neuropsychiatric symptoms of PMDD by modulating GABAergic signalling and the HPA axis, with potential benefits for alleviating fatigue, anxiety and stress reactivity.13  It may be particularly useful for clients with evidence of heightened HPA axis dysregulation and stress sensitivity. 
  • Chaste tree (Vitex agnus-castus) has demonstrated significant clinical benefit for improving PMS symptoms including mood stability, irritability, anxiety, headache and breast tenderness.  It exerts these effects through modulation of the hypothalamic-pituitary-ovarian (HPO) axis, decreasing stress induced prolactin secretion via dopaminergic compounds.14  Chaste tree may be particularly useful in cases where cycle irregularity or luteal insufficiency coexists.
  • Passionflower (Passiflora incarnata) is a gentle nervine, used for relief from anxiety and irritability.   It exerts these effects through modulation of GABAergic and monoaminergic pathways.15  Passionflower is useful for acute prescribing during the luteal phase for relieving psychological symptoms associated with PMDD.
  • Saffron (Crocus sativus) shows promising antidepressant and anxiolytic effects relevant to PMDD's affective symptoms.  These effects are mediated by active compounds, crocin and safranal, which modulate the monoaminergic pathway by inhibiting reuptake of dopamine, serotonin and norepinephrine.  Most clinical studies have observed Saffron's benefit for PMDD when dosed daily (30 mg dried stigma, for comparison 1 mL of a 1:20 liquid extract is equivalent to 50 mg dried stigma) for two weeks during the luteal phase for minimum of two menstruation cycles.16
  • Skullcap (Scutellaria lateriflora) is a nervine herb that can be used to manage PMDD symptoms by soothing the nervous system, reducing emotional reactivity and easing anger or restlessness.17  Skullcap can be beneficial for acute prescribing during the luteal phase for relieving psychological symptoms associated with PMDD.
  • St John's wort (Hypericum perforatum) exerts notable anti-depressant effects by inhibiting reuptake of serotonin, thereby enhancing neurotransmitter availability, much alike SSRIs.18  St. John's wort has proved clinically efficacious for the treatment of common physical and behavioural symptoms of PMS.19  It is important to consider interactions between St. John's wort and SSRIs or contraceptives.
  • Turmeric (Curcuma longa) contains the widely studied active compound, curcumin.  A clinical study evaluating its effects on PMS found curcumin to significantly reduce mean scores of mood, behavioural and physical symptoms.  Study participants took to capsules (each containing 100 mg curcumin extract) twice daily for seven days prior to menstruation and for three days during menstruation.  Curcumin exerts these effects by modulating neurotransmitter (serotonin, dopamine and norepinephrine) levels that are involved in mood and behaviour regulation.  Additionally, curcumin may help alleviate physical symptoms by downregulating COX-2 activity and inhibiting prostaglandin synthesis, thereby reducing inflammation associated with pain and swelling.20 

The key is individualisation.  Some clients will respond well to these herbal interventions; others may require stronger emphasis on psychological or pharmacological support.

4. Lifestyle medicine

Perhaps the most impactful interventions in PMDD are those that support nervous system regulation.  This may include:

  • Regular exercise (shown to improve mood and reduce symptom severity)
  • Sleep hygiene and circadian alignment
  • Stress reduction practices (breathwork, mindfulness, meditation).

These approaches do not eliminate hormonal fluctuation, but they can change how the body responds to it.

5. Psychological and somatic therapies 

Psychotherapy is increasingly recognised as a key component of PMDD care.  A 2024 randomised controlled trial demonstrated that emotion-focused therapy significantly improved emotional regulation and symptom severity in individuals with PMDD.21

Other beneficial approaches may include:

  • Cognitive behavioural therapy (CBT)
  • Trauma-informed therapies (EMDR, somatic experiencing)
  • Mindfulness-based interventions.

These approaches may be particularly effective for improving emotional regulation and coping capacity, as well as supporting individuals with coexisting trauma histories.  They can support clients to develop greater awareness of cyclical patterns and build strategies for navigating the luteal phase.

Equally important is reframing the experience.  Understanding PMDD as a physiological and neurological condition, rather than a personal failing, can significantly reduce shame and improve engagement with treatment.

6. Pharmacological interventions (collaborative care)

While Naturopaths cannot prescribe pharmaceuticals, understanding conventional treatments supports collaborative care.

SSRIs are the first-line option and may be used:

  • Continuously
  • Luteal phase only.

They appear to act rapidly in PMDD, potentially via modulation of neurosteroid and GABA pathways.  Hormonal therapies that suppress ovulation (eg oral contraceptives and GnRH agonists) may also be indicated in severe cases.2  A collaborative approach ensures that clients receive the level of support required, while benefiting from the broader, systems-based care that naturopathy offers.

Emerging directions: Where the research is heading 

Research into PMDD continues to evolve, with several promising areas of investigation.  Neurosteroid modulators such as sepranolone aim to directly address sensitivity to allopregnanolone by modulating GABA-A receptor response.22  Early clinical trials have demonstrated symptom reduction, although further research is required.

The role of the gut-brain axis in PMDD is also gaining interest, particularly in relation to oestrogen metabolism and immune signalling.  The bidirectional relationship between the gut microbiota and steroid hormones, and the impact of diet, drugs and inflammation on both, warrants further investigation into the microbiome's role in PMDD.23

Circadian rhythm regulation is another area of relevance.  Disruptions in sleep and light exposure can influence both mood and hormonal signalling, suggesting that chronobiology may play a role in PMDD symptom expression.24

Key takeaways

  • Sensitivity, not deficiency: PMDD is a complex neuroendocrine condition, driven by sensitivity to normal hormonal changes rather than hormonal imbalance itself.
  • Symptom tracking is vital: Cyclical symptom patterns are key to accurate diagnosis
  • Screen for trauma: It can significantly influence treatment pathways and outcomes.
  • Prioritise nervous system regulation: Stress physiology is central to symptom expression.
  • Collaborative care is key: Given the increased risk of suicidal ideation during the luteal phase in PMDD, collaboration with mental health providers is crucial.
  • Integrative approaches yield best results: Combining nutrition, lifestyle, herbal and psychological support with pharmacological treatment when necessary is vital for enhancing client outcomes.

References

1.      Arora, A., Chakraborty, S., & Pandey, R. (2025). Understanding premenstrual dysphoric disorder from a psychosomatic and a sensory perspective. Frontiers in Global Women’s Health, 6. https://doi.org/10.3389/fgwh.2025.1595083

2.      Mishra, S., Elliott, H., & Marwaha, R. (2023, February 19). Premenstrual Dysphoric Disorder. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK532307/

3.      Hall, E., & Steiner, M. (2013). Serotonin and female psychopathology. Women’s Health, 9(1), 85–97. https://doi.org/10.2217/whe.12.64

4.      Cheng, M., Jiang, Z., Yang, J., Sun, X., Song, N., Du, C., Luo, Z., & Zhang, Z. (2025). The role of the neuroinflammation and stressors in premenstrual syndrome/premenstrual dysphoric disorder: A review. Frontiers in Endocrinology, 16. https://doi.org/10.3389/fendo.2025.1561848

5.      Sultana, A., Rahman, K., Heyat, M. B. B., Sumbul, Akhtar, F., & Muaad, A. Y. (2022). Role of inflammation, oxidative stress, and mitochondrial changes in premenstrual psychosomatic behavioral symptoms with anti-inflammatory, antioxidant herbs, and nutritional supplements. Oxidative Medicine and Cellular Longevity, 2022, 1–29. https://doi.org/10.1155/2022/3599246

6.      Trout, K. K., Basel-Brown, L., Rickels, M. R., Schutta, M. H., Petrova, M., Freeman, E. W., Tkacs, N. C., & Teff, K. L. (2008). Insulin Sensitivity, Food Intake, and Cravings with Premenstrual Syndrome: A Pilot Study. Journal of Women’s Health, 17(4), 657–665. https://doi.org/10.1089/jwh.2007.0594

7.      Sarris, J., & Wardle, J. (2019). Clinical Naturopathy. Elsevier Health Sciences.

8.      Hechtman, L. (2019). Clinical naturopathic medicine (2nd ed.). Elsevier.

9.      Arab, A., Rafie, N., Askari, G., & Taghiabadi, M. (2020). Beneficial role of calcium in premenstrual syndrome: A systematic review of current literature. International Journal of Preventive Medicine, 11. https://doi.org/10.4103/ijpvm.IJPVM_243_19

10. Heidari, H., Amani, R., Feizi, A., Askari, G., Kohan, S., & Tavasoli, P. (2019). Vitamin D supplementation for premenstrual syndrome-related inflammation and antioxidant markers in students with vitamin D deficient: A randomized clinical trial. Scientific Reports, 9(1). https://doi.org/10.1038/s41598-019-51498-x

11. Porri, D., Biesalski, H. K., Limitone, A., Bertuzzo, L., & Cena, H. (2021). Effect of magnesium supplementation on women’s health and well-being. NFS Journal, 23, 30–36. https://doi.org/10.1016/j.nfs.2021.03.003

12. Lastretti, M., Campedelli, L., Scarparo, T., Spagna, S., Cicoli, A., Faa, G., & D’Aleo, E. (2026). Omega-3 fatty acids and mood disorders: A critical narrative review. Lipidology, 3(1), 2. https://doi.org/10.3390/lipidology3010002

13. Zamani, M., Neghab, N., & Torabian, S. (2012). Therapeutic effect of Vitex agnus castus in patients with premenstrual syndrome. Acta Medica Iranica, 50(2), 101–106. https://pubmed.ncbi.nlm.nih.gov/22359078/

14. Soares, M., Theresa, A., Delarue, R., Wagner, F., & Henrique, O. (2025). A systematic review of neurobiological mechanisms of Passiflora: Beyond GABA modulation. BioChem, 5(3), 21. https://doi.org/10.3390/biochem5030021

15. Rajabi, F., Rahimi, M., Sharbafchizadeh, M., & Tarrahi, M. (2020). Saffron for the management of premenstrual dysphoric disorder: A randomized controlled trial. Advanced Biomedical Research, 9(1), 60. https://doi.org/10.4103/abr.abr_49_20

16. Marciano, M., & Vizniak, N. A. (2020). Evidence informed botanical medicine. Professional Health Systems Inc.

17. Merk, V. M., Boonen, G., & Butterweck, V. (2025). St. John’s wort for depression: From neurotransmitters to membrane plasticity. International Journal of Molecular Sciences, 26(24), 11925. https://doi.org/10.3390/ijms262411925

18. Canning, S., Waterman, M., Orsi, N., Ayres, J., Simpson, N., & Dye, L. (2010). The efficacy of Hypericum perforatum (St Johnʼs wort) for the treatment of premenstrual syndrome. CNS Drugs, 24(3), 207–225. https://doi.org/10.2165/11530120-000000000-00000

19. Khayat, S., Fanaei, H., Kheirkhah, M., Moghadam, Z. B., Kasaeian, A., & Javadimehr, M. (2015). Curcumin attenuates severity of premenstrual syndrome symptoms: A randomized, double-blind, placebo-controlled trial. Complementary Therapies in Medicine, 23(3), 318–324. https://doi.org/10.1016/j.ctim.2015.04.001

20. Namysł, M., Matczak, S., Dachowska, S., Haraj, J., Majcherek, E., Sobkowiak, M., Bieniek, M., & Kinga Woźniak. (2026). Withania somnifera in women’s hormonal modulation: A narrative review with implications for polycystic ovary syndrome and premenstrual syndrome. Cureus. https://doi.org/10.7759/cureus.101431

21. Saeideh Izadi Dehnavi, Seyede Salehe Mortazavi, Mohammad Arash Ramezani, Banafshe Gharraee, & Ashouri, A. (2024). Emotion-focused therapy for women with premenstrual dysphoric disorder: A randomized clinical controlled trial. BMC Psychiatry, 24(1). https://doi.org/10.1186/s12888-024-05681-8

22. Bäckström, T., Ekberg, K., Hirschberg, A. L., Bixo, M., Epperson, C. N., Briggs, P., Panay, N., & O’Brien, S. (2021). A randomized, double-blind study on efficacy and safety of sepranolone in premenstrual dysphoric disorder. Psychoneuroendocrinology, 133, 105426. https://doi.org/10.1016/j.psyneuen.2021.105426

23. Nabeh, O. A. (2023). New insights on the impact of gut microbiota on premenstrual disorders. Will probiotics solve this mystery? Life Sciences, 321, 121606. https://doi.org/10.1016/j.lfs.2023.121606

24. Yamak, Ö. A., Şentürk, Ş., Kağıtçı, M., Altinsoy, C., & Puşuroğlu, M. (2025). The relationship between premenstrual syndrome and circadian rhythm, depressive mood, and anxiety. Scientific Reports, 15(1). https://doi.org/10.1038/s41598-025-23040-9

Back to blog